Evolus (EOLS) Free Cash Flow (2017 - 2026)
Evolus (EOLS) posted Free Cash Flow of -$10.0 million for Q1 2026, down 182.08% on a QoQ basis from $12.1 million in Q4 2025, and up 37.53% year-over-year from -$7.2 million in Q1 2025.
Evolus (EOLS) Free Cash Flow (2017 - 2026) Analysis & Trends
Evolus' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$10.0 million for Q1 2026.
- Quarterly Free Cash Flow rose 37.53% year-over-year to -$10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.3 million (down 68.18% YoY) and the FY2025 annual result came in at -$47.3 million, down 142.8% from the prior year.
- Free Cash Flow was -$10.0 million for Q1 2026 at Evolus, down from $12.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $12.1 million in Q4 2025 and bottomed at -$38.2 million in Q1 2022.
- A 5-year average of -$11.7 million and a median of -$10.9 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 358.06% — and 2024, when it soared 561.12%.
- Evolus' Free Cash Flow stood at -$9.6 million in 2022, then jumped by 106.86% to $661000.0 in 2023, then surged by 561.12% to $4.4 million in 2024, then soared by 177.8% to $12.1 million in 2025, then tumbled by 182.08% to -$10.0 million in 2026.
- Business Quant data shows EOLS's Free Cash Flow at -$10.0 million in Q1 2026, $12.1 million in Q4 2025, and -$15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -9.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.96 Mn |
| Mar 31, 2026 | -9.96 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Sep 30, 2025 | -15.87 Mn |
| Sep 30, 2025 | -15.87 Mn |
| Jun 30, 2025 | -27.59 Mn |
| Jun 30, 2025 | -27.59 Mn |
| Mar 31, 2025 | -15.95 Mn |
| Mar 31, 2025 | -15.95 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Sep 30, 2024 | -5.43 Mn |
| Sep 30, 2024 | -5.43 Mn |
| Jun 30, 2024 | -7.54 Mn |
| Jun 30, 2024 | -7.54 Mn |
| Mar 31, 2024 | -10.87 Mn |
| Mar 31, 2024 | -10.87 Mn |
| Dec 31, 2023 | 661,000.00 |
| Dec 31, 2023 | 661,000.00 |